Article info

Download PDFPDF
Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort

Authors

  • Sandra Rotea-Salvo Service of Pharmacy, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, Spain PubMed articlesGoogle scholar articles
  • Alejandro Martínez-Pradeda Service of Pharmacy, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, Spain PubMed articlesGoogle scholar articles
  • Carla Fernández-Oliveira Service of Pharmacy, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, Spain PubMed articlesGoogle scholar articles
  • Victor Giménez-Arufe Service of Pharmacy, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, Spain PubMed articlesGoogle scholar articles
  • Vanesa Balboa-Barreiro Clinical Epidemiology and Biostatistics Unit, Biomedical Research Institute of A Coruña (INIBIC), Universitary Hospital of A Coruña (CHUAC), SERGAS. University of A Coruña (UDC), A Coruña, Galicia, Spain PubMed articlesGoogle scholar articles
  • Luis Margusino-Framiñán Service of Pharmacy, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, SpainDivision of Clinical Virology, Biomedical Research Institute of A Coruña (INIBIC), Universitary Hospital of A Coruña (CHUAC), SERGAS. University of A Coruña (UDC), A Coruña, Galicia, Spain PubMed articlesGoogle scholar articles
  • Álvaro Mena-De-Cea Division of Clinical Virology, Biomedical Research Institute of A Coruña (INIBIC), Universitary Hospital of A Coruña (CHUAC), SERGAS. University of A Coruña (UDC), A Coruña, Galicia, SpainService of Infectious Internal Medicine, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, Spain PubMed articlesGoogle scholar articles
  • Pilar Vázquez-Rodríguez Division of Clinical Virology, Biomedical Research Institute of A Coruña (INIBIC), Universitary Hospital of A Coruña (CHUAC), SERGAS. University of A Coruña (UDC), A Coruña, Galicia, SpainService of Infectious Internal Medicine, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, Spain PubMed articlesGoogle scholar articles
  • Ángeles Castro-Iglesias Division of Clinical Virology, Biomedical Research Institute of A Coruña (INIBIC), Universitary Hospital of A Coruña (CHUAC), SERGAS. University of A Coruña (UDC), A Coruña, Galicia, SpainService of Infectious Internal Medicine, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, Spain PubMed articlesGoogle scholar articles
  • Soledad López-Calvo Division of Clinical Virology, Biomedical Research Institute of A Coruña (INIBIC), Universitary Hospital of A Coruña (CHUAC), SERGAS. University of A Coruña (UDC), A Coruña, Galicia, SpainService of Infectious Internal Medicine, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, Spain PubMed articlesGoogle scholar articles
  • Isabel Martín-Herranz Service of Pharmacy, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, Spain PubMed articlesGoogle scholar articles
  • Enrique Míguez-Rey Division of Clinical Virology, Biomedical Research Institute of A Coruña (INIBIC), Universitary Hospital of A Coruña (CHUAC), SERGAS. University of A Coruña (UDC), A Coruña, Galicia, SpainService of Infectious Internal Medicine, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, Spain PubMed articlesGoogle scholar articles
  • Purificación Cid-Silva Service of Pharmacy, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, SpainDivision of Clinical Virology, Biomedical Research Institute of A Coruña (INIBIC), Universitary Hospital of A Coruña (CHUAC), SERGAS. University of A Coruña (UDC), A Coruña, Galicia, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Purificación Cid-Silva, Service of Pharmacy, Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain; purificacion.cid.silva{at}sergas.es
View Full Text

Citation

Rotea-Salvo S, Martínez-Pradeda A, Fernández-Oliveira C, et al
Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort

Publication history

  • Received May 18, 2021
  • Accepted September 28, 2021
  • First published October 14, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.